fig1

Figure 1. Selection of the Medicinal Products. The graphics represents the methods used by the Task Force group to select cases of drug repurposing in rare diseases. The medicinal products initially approved for common or rare indications were all repurposed into a new rare disease. Approvals for the original and new indication were granted by the same regulatory authority. Medicinal products with an extension of the same rare disease indication were excluded from the analysis.